CASI Pharmaceuticals
Quarterly Financials
| Values in thousands | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|
Revenue | $4,175 | $6,240 | $13,356 | $7,793 |
Gross Profit | 2,058 | 3,619 | 3,228 | 4,045 |
EBITDA | -10,957 | -10,553 | -10,340 | -8,085 |
EBIT | -12,914 | -8,464 | ||
Net Income | -13,375 | -10,750 | -14,370 | -8,395 |
Net Change In Cash | 4,175 | 6,240 | 13,356 | 7,793 |
Cash | 6,740 | 10,897 | 13,468 | 16,537 |
Basic Shares | 15,505 | 15,492 | 15,492 | 15,294 |
Annual Financials
| Values in thousands | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
Revenue | $28,537 | $33,879 | $43,107 | $30,168 |
Gross Profit | 11,146 | 20,052 | 27,280 | 17,611 |
EBITDA | -34,867 | -21,539 | -24,069 | -32,747 |
EBIT | -37,198 | -25,280 | -26,491 | -35,842 |
Net Income | -39,258 | -26,938 | -39,411 | -37,772 |
Net Change In Cash | 28,537 | 33,879 | 43,107 | 30,168 |
Cost of Revenue | -18,360 | |||
Free Cash Flow | -29,464 | -22,208 | -26,700 | -42,342 |
Cash | 13,468 | 17,083 | 47,112 | 38,704 |
Basic Shares | 15,340 | 13,360 | 13,647 | 13,610 |
Earnings Calls
| Quarter | EPS |
|---|---|
2025-06-30 | -$0.86 |
2025-03-31 | -$0.69 |
2024-12-31 | -$0.75 |
2024-09-30 | -$0.55 |
